Mytos launched an automated CDMO built around its iDEM automation technology at the Cell and Gene Therapy Catapult’s Stevenage site, targeting scalable manufacture of stem‑cell derived therapies. The facility will aim for clinical readiness by September 2026 with capacity claims up to 1,500 autologous or 25,000 allogeneic doses annually and expandable cleanroom space. Mytos positioned its approach as lowering per‑dose costs and tech‑transfer friction compared with manual manufacturing. By automating long, operator‑intensive workflows, Mytos seeks to address a central obstacle to commercializing regenerative medicines: high manufacturing cost and limited capacity. The partnership with CGT Catapult offers access to an established GMP ecosystem and could accelerate sponsors’ transitions from R&D to clinical manufacture.